H Faatz, N Feltgen, M Gutfleisch, B Heimes-Bussmann, T U Krohne, S Liakopoulos, R Liegl, A Lommatzsch, P Mussinghoff, M Rehak, S Schmitz-Valckenberg, G Spital, B Stanzel, F Ziemssen, B Hägele, C Junkes, M Porstner, J Vögeler, B Gmeiner, D Pauleikhoff
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is the standard treatment for patients with neovascular age-related macular degeneration (nAMD). In addition to the approved substances ranibizumab (Lucentis®, Novartis) and aflibercept (Eylea®, Bayer), bevacizumab (Avastin®, Roche) is also available. Furthermore, brolucizumab (Beovu®, Novartis) has been approved and has been available in Germany since April 2020. The multicenter, noninterventional prospective BLUE SKY study investigates brolucizumab treatment with different schemes in 600 treatment-naive and pretreated nAMD patients in routine clinical practice over a 24-month period...
September 20, 2022: Ophthalmologie